NCT03294850View on ClinicalTrials.gov

Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

November 14, 2019

Study Completion Date

September 11, 2020

Conditions
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
PROCEDURE

Bariatric surgery

Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied

DEVICE

HepQuant SHUNT Dual Cholate Liver Diagnostic Kit

For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.

Trial Locations (1)

32804

Translational Research Institute for Metabolism and Diabetes, Orlando

All Listed Sponsors
lead

AdventHealth Translational Research Institute

OTHER

NCT03294850 - Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery | Biotech Hunter | Biotech Hunter